story of the week
Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
J. Clin. Oncol 2017 Mar 14;[EPub Ahead of Print], A Bardia, IA Mayer, JR Diamond, RL Moroose, SJ Isakoff, AN Starodub, NC Shah, J O'Shaughnessy, K Kalinsky, M Guarino, V Abramson, D Juric, SM Tolaney, J Berlin, WA Messersmith, AJ Ocean, WA Wegener, P Maliakal, RM Sharkey, SV Govindan, DM Goldenberg, LT VahdatFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.